Lead Product(s) : SGX-001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Vi Partners
Deal Size : $11.6 million
Deal Type : Series A Financing
Somagenetix Secures CHF 10M to Advance Gene Therapy For CGD
Details : The funds will enable Somagenetix to advance its leading gene therapy-candidate, SGX-001, into a clinical trial for the treatment of p47 Chronic Granulomatous Disease (CGD).
Product Name : SGX-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 10, 2024
Lead Product(s) : SGX-001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Vi Partners
Deal Size : $11.6 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Charcot Marie Tooth Association
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The primary goal of the collaboration is to evaluate the benefit of Addex’s proprietary positive allosteric modulator’s (PAM’s) targeting the gamma-aminobutyric acid subtype B (GABAB) receptor in rodent models of CMT1A.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 22, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Charcot Marie Tooth Association
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bitopertin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Disc medicine
Deal Size : $200.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Disc Medicine will obtain exclusive, global rights to and be responsible for all development, manufacturing, and commercialization of bitopertin and related back up compounds.
Product Name : RO4917838
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2021
Lead Product(s) : Bitopertin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Disc medicine
Deal Size : $200.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Branaplam
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis receives US FDA Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
Details : In preclinical models, branaplam has been shown to reduce levels of mutant huntingtin protein. In addition, during the investigation of branaplam in spinal muscular atrophy (SMA), it was also observed to reduce huntingtin messenger RNA (mRNA) in SMA pati...
Product Name : LMI070
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2020
Lead Product(s) : Branaplam
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VS-01
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VS-01 is an innovative liposomal-based detoxification therapy that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during liver and kidney failures.
Product Name : VS-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : VS-01
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APR-OD031
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)
Details : First mix of amino acids having a pharmacological primary mode of action designed to reduce and control Phenylalanine fluctuations.
Product Name : APR-OD031
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2020
Lead Product(s) : APR-OD031
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable